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Abstract
Elevated levels of acute-phase serum amyloid A (A-SAA) cause amyloidosis and are a risk factor for atherosclerosis and its
clinical complications, type 2 diabetes, as well as various malignancies. To investigate the genetic basis of A-SAA levels, we
conducted the first genome-wide association study on baseline A-SAA concentrations in three population-based studies
(KORA, TwinsUK, Sorbs) and one prospective case cohort study (LURIC), including a total of 4,212 participants of European
descent, and identified two novel genetic susceptibility regions at 11p15.5-p13 and 1p31. The region at 11p15.5-p13
(rs4150642; p=3.20610
2111) contains serum amyloid A1 (SAA1) and the adjacent general transcription factor 2 H1 (GTF2H1),
Hermansky-Pudlak Syndrome 5 (HPS5), lactate dehydrogenase A (LDHA), and lactate dehydrogenase C (LDHC). This region
explains 10.84% of the total variation of A-SAA levels in our data, which makes up 18.37% of the total estimated heritability.
The second region encloses the leptin receptor (LEPR) gene at 1p31 (rs12753193; p=1.22610
211) and has been found to be
associated with CRP and fibrinogen in previous studies. Our findings demonstrate a key role of the 11p15.5-p13 region in
the regulation of baseline A-SAA levels and provide confirmative evidence of the importance of the 1p31 region for
inflammatory processes and the close interplay between A-SAA, leptin, and other acute-phase proteins.
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Introduction
Serum amyloid A (SAA) is a sensitive marker of the acute
inflammatory state. Its isoforms are expressed constitutively (C-
SAA) and show a rapid (up to 1000-fold) increased expression in
response to inflammatory stimuli such as trauma, infection, injury,
and stress during the acute phase (A-SAA) [1]. The high inductive
capacity along with a high conservation of genes and proteins
throughout evolution of vertebrates and invertebrates suggests that
A-SAA plays a key role in pathogen defence and probably
functions as an immune-effector molecule [1]. Acute inflammation
has mainly beneficial effects in restoring homeostasis. However, in
recent years, clinical and epidemiological studies have gathered
substantial evidence that A-SAA is associated with obesity [2] and
that prolonged and recurrent chronic infection as well as
inflammation is causally involved in the pathogeneses of
amyloidosis [1]. Furthermore, it induces, promotes, or influences
susceptibility to several chronic diseases such as atherosclerosis and
its clinical complications [3–9], type 2 diabetes [10,11], and
various malignancies [12]. The SAA gene family is located within
150 kb at chromosome 11 and comprises of four genes: SAA1 and
SAA2, the bona fide acute-phase SAA isoforms, SAA3, a pseudogene
in humans, and SAA4, a low level expressed gene coding for C-
SAA [13,14]. A-SAA expression is regulated by a variety of
stimuli, including the pro-inflammatory cytokines TNF-a and IL-
6, as well as glucocorticoids [15,16]. Like other acute-phase
proteins, A-SAA is expressed primarily by the liver [17]. However,
extra-hepatic expression has been reported for different cell lines
like epithelial cells, monocyte and macrophage cells, most
endothelial cells, adipocytes, atherosclerotic lesions, and smooth
muscle cells [17]. Twin studies suggest a substantial genetic
contribution to baseline A-SAA concentrations with heritability
estimates of 59% (95% confidence interval, 49–67%) [18]. The
identification of genetic variants that are predisposed to elevated
levels of A-SAA could provide important clues to the immune
response pathways involved in the regulation of A-SAA levels
which might also be of relevance for related clinical entities. In the
past, association analyses between genetic variants and A-SAA
levels were limited and restricted to allelic variants of SAA genes
and protein concentrations [19–21].
We therefore conducted the first genome-wide association study
on baseline A-SAA concentrations. In a meta-analysis of four
genome-wide scans (KORA S4, LURIC, TwinsUK and Sorbs) we
included 4,212 participants of European descent. Additionally, in
order to account for known gender-specific differences in the
regulation of A-SAA [22,23] we stratified the analysis by gender.
Results
In the present meta-analysis of four genome wide scans 106 SNPs
distributed across two regions showed genome-wide significant
associations with p-values below the threshold of 5610
28 (Figure 1,
Table S1). Table 1 shows study specific results for the top hits within
the two regions and three identified subregions (see below) of the
meta-analysis as well as an additional region for men in the gender
stratified analysis. Genotypic mean levels are provided in Table S2.
Results of the single genome-wide studies were consistent across all
four studies regarding the direction and magnitude of the effects. In
addition, results were consistent between different genotyping
technologies (Table S3). No deviations from the Hardy-Weinberg-
Equilibrium were observed. The variable of inter-study heteroge-
neity (I
2) showed homogeneity at the 1p31 locus. At the 11p15.5-
p13 locus we observed I
2 values that indicated a more distinct
heterogeneity. This reflects the relatively large and varying beta
values and differences in the minor allele frequency (Table S1).
However, taking into account that this locus was clearly significantly
associated with A-SAA in all studies included in the meta-analysis,
results of the meta-analysis are reported based on a fixed effect
model.
The first region (193.3 kb of length) resides at 11p15.5-p13 and
includes SAA1 one of the structure genes of A-SAA. Within this
region the strongest association was found for two highly
correlated intronic polymorphisms of the general transcription
factor 2 H1 (GTF2H1) gene, rs4150642 (p=3.20610
2111) and
rs7103375 (p=3.26610
2111) (Figure 2A). These two top hits show
modest correlation (r
2#0.376) with other significantly associated
SNPs within this region. When the structure of correlation and
explained variances within the region were analysed three mostly
independent subregions were identified (Table S4, Figure 2B–2D).
The first subregion encloses the 59 end of SAA1 (Figure 2B) with
strongest association for rs4638289 (p=2.77610
253). The other
two subregions harbour the genes Hermansky-Pudlak Syndrome 5
(HPS5) and GTF2H1 (Figure 2C) and lactate dehydrogenase A
and C (LDHA and LDHC) (Figure 2D) with strongest associations
for rs4353250 (p=1.68610
251) and rs2896526 (p=4.12610
222),
two intronic polymorphisms of HPS5 and LDHA, respectively.
The second region was detected at 1p31 (Figure 2E). All 38
significantly associated variants cluster around the 39 end of the
leptin receptor gene (LEPR). The most significantly associated
SNP, rs12753193, (p=1.22610
211) is located downstream of
LEPR.
All associations were consistent in the KORA S4 validation
analyses (Table 1 for the top hits, Table S5 for all SNPs selected
for validation).
The entire regression model (including the top SNPs of the two
genomic regions (rs4150642 and rs12753193), age, gender and
BMI) explains 19.32% of the total variation of A-SAA in our data.
With an explained variance of 10.84% for the top SNP
(rs4150642) of the 11p15.5-p13 locus (5.57% for rs4638289 of
the SAA1 subregion, 5.34% for rs4353250 of the HPS5/GTF2H1
subregion, and 2.37% for rs2896526 of the LDHA/LDHC
subregion; Table S4) and 0.93% for the top SNP (rs12753193)
of the 1p31 locus the identified genomic regions account for a
major part of such variance.
When the analysis was stratified by gender, one additional SNP
(rs549485) located about 350 kb apart from the SAA1 subregion at
11p14 in the secretion regulating guanine nucleotide exchange
factor (SERGEF) gene showed a borderline significant association
with A-SAA levels in men (p=2.76610
28) in the meta-analysis. In
the validation analysis the association between two highly
correlated SNPs within this region (rs493767 and rs550659,
r
2=0.961) and A-SAA levels was also borderline significant
(p=8.50610
23 and p=1.65610
22, respectively). No significant
differences between men and women were found within the
regions identified in the overall meta-analysis (data not shown).
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Based on a meta-analysis of four genome-wide association
studies including 4,212 participants of European descent two novel
genetic susceptibility regions were identified to be associated with
baseline A-SAA concentrations. With 11.68% explained variance
in our data, which makes up 19.76% of the total estimated
heritability of 59%, these two regions seem to have a major impact
on baseline A-SAA concentrations. The region at 11p15.5-p13
accounts for most of the explained variance. Its SAA1 subregion
contains part of a highly conserved region between the two bona
fide acute-phase structure genes SAA1 and SAA2, which consist of at
least 5 and 2 allelic variants, respectively [1,24]. These two genes
are concurrently induced during the acute-phase [1], and cluster
within 18 kb of each other in a head to head arrangement [25].
This study is the first presenting the complex genetic architecture
of A-SAA levels at this locus. In the identified region, there has
been evidence of regulatory elements like C/EBPalpha and C/
EBPbeta (http://genome.ucsc.edu), which are necessary for the
full responsiveness to IL-1b and IL-6 either alone or in
combination [1]. Our finding underlines the high functional
potential for this region.
The adjacent GTF2H1 is a basal transcription factor involved in
nucleotide excision repair of DNA and RNA transcription by
RNA polymerase II [26]. HPS5 encodes a protein, which is
probably involved in organelle biogenesis associated with mela-
nosomes and platelet dense granule, its mutations lead to a
homonymous clinical entity [27]. And LDHA and LDHC, which
are expressed in muscle tissue and in testes, respectively, encode
for lactate dehydrogenase, an enzyme that catalyzes the
interconversion of lactate and pyruvate [28].
Variants of the GTF2H1 gene have been recently found to be
associated with lung cancer in a Chinese population [29].
Furthermore, it was demonstrated that LDHA is involved in
tumour genecity and its reduction causes bioenergetic and
oxidative stress leading to cell death [30–32]. Finally, Kosolowski
et al. [33] found LDHC to be expressed in several types of tumour
cell lines. It is thought, that recurrent or persistent chronic
inflammation may play a role in carcinogenesis by causing DNA
damage, inciting tissue reparative proliferation and/or by creating
an environment that is enriched with tumour-promoting cytokines
and growth factors [12]. Furthermore, SAA synthesis could be
found in human carcinoma metastases and cancer cell lines [17].
As the approach taken in this study is observational in nature it
is not possible to draw causal inferences. For that reason, it could
be possible that not genes, but small regulatory elements may be
responsible for the findings. This is most likely the case as the
identified region contains one structure gene and the adjacent
region. In any case, the major impact on baseline A-SAA
concentrations demonstrates a key role of the 11p15.5-p13 region
in the regulation of inflammation. Therefore, the identification of
causal variants and their impact on diseases related to elevated
baseline A-SAA concentrations represent promising targets for
future functional and epidemiological studies.
The second region was found on chromosome 1p31, harbour-
ing the LEPR gene locus. Leptin, an important circulating signal
for the regulation of body weight, was found to be correlated with
SAA concentrations independently of BMI, and both were
expressed in adipose tissue [34]. In the KORA F3 study (Text
S1) a moderate but significant correlation was found between
circulating A-SAA and leptin concentrations in blood in 181
Figure 1. Manhattan plot and quantile-quantile plot of the results of the meta-analysis on baseline A-SAA levels. The Manhattan plot
on the left hand side displays all analyzed SNPs with their calculated p-values (p-values below the threshold of genome-wide significance are
coloured red). The quantile-quantile plot on the right hand side points out the observed significant associations beyond those expected by chance.
doi:10.1371/journal.pgen.1001213.g001
Author Summary
An elevated level of acute-phase serum amyloid A (A-SAA),
a sensitive marker of the acute inflammatory state with
high heritability estimates, causes amyloidosis and is a risk
factor for atherosclerosis and its clinical complications,
type 2 diabetes, as well as various malignancies. This study
describes the first genome-wide association study on
baseline A-SAA concentrations. In a meta-analysis of four
genome-wide scans totalling 4,212 participants of Euro-
pean descent, we identified two novel genetic suscepti-
bility regions on chromosomes 11 and 1 to be associated
with baseline A-SAA concentrations. The chromosome 11
region contains the serum amyloid A1 gene and the
adjacent genes and explains a high percentage of the total
estimated heritability. The chromosome 1 region is a
known genetic susceptibility region for inflammation.
Taken together, we identified one region, which seems
to be of key importance in the regulation of A-SAA levels
and represents a novel potential target for the investiga-
tion of related clinical entities. In addition, our findings
indicate a close interplay between A-SAA and other
inflammatory proteins, as well as a larger role of a known
genetic susceptibility region for inflammatory processes as
it has been assumed in the past.
Genome-Wide Association Study on Acute-Phase SAA
PLoS Genetics | www.plosgenetics.org 3 November 2010 | Volume 6 | Issue 11 | e1001213participants with measurements of both proteins (Spearman
correlation=0.25, p=7610
24). So far it is unclear whether leptin
influences SAA expression directly or via the leptin stimulated
cytokines, IL-6 and TNF-a [34]. LEPR is a single transmembrane
receptor of the cytokine receptor family most related to the gp130
signal-transducing component of the IL-6 receptor, the granulo-
cyte colony-stimulating factor (GCSF) receptor, and the Leukae-
mia Inhibitory Factor (LIF) receptor, all of which are thought to
play an essential role in the inflammatory process [35,36].
Previous studies have provided evidence of an association of the
LEPR gene locus with CRP and fibrinogen [37–40], which were
both correlated with A-SAA in the KORA S4 study (Text S1)
(CRP: Spearman correlation=0.58, p=3.22610
2155, and fibrin-
ogen: Spearman correlation=0.31, p=3.89610
241; N=1734).
The finding gives confirmative evidence of the importance of the
LEPR gene locus for inflammatory processes and the close
relationship between leptin, A-SAA, CRP and fibrinogen.
Furthermore, in the gender stratified analysis one region
containing SERGEF was identified to be presumably associated
with A-SAA in men. The adjacency of this identified region to the
SAA gene family suggests that regulatory elements may be
responsible for this signal. However, the association with A-SAA
levels was only borderline significant in our study and therefore
awaits replication.
Table 1. Study-specific results for the hits within the regions/subregions.
SNP chr
region/
subregion study
effect
allele
other
allele imp
effect allele
freq n beta se(beta) p
rs4150642 11 11p15.5-p13 KORA S4 G C I 0.200 1785 0.529 0.032 1.92E-58
region LURIC G C I 0.212 961 0.569 0.075 6.51E-14
Sorbs G C I 0.212 883 0.524 0.042 1.22E-32
TwinsUK G C I 0.109 550 0.358 0.050 8.27E-13
combined G C - 0.193 4179 0.501 0.022 3.20E-111
validation G C G 0.217 2082 0.473 0.029 7.41E-58
rs4638289 11 SAA1 KORA S4 A T I 0.347 1785 0.323 0.027 4.95E-31
subregion LURIC A T I 0.358 961 0.235 0.063 2.17E-04
Sorbs A T I 0.320 883 0.405 0.044 1.71E-19
TwinsUK A T I 0.214 514 0.206 0.041 5.70E-07
combined A T - 0.327 4143 0.305 0.020 2.77E-53
validation A T G 0.332 2091 0.292 0.025 1.61E-30
rs4353250 11 HPS5/GTF2H1 KORA S4 T C I 0.339 1785 0.278 0.027 1.06E-24
subregion LURIC T C I 0.351 961 0.364 0.060 2.21E-09
Sorbs T C I 0.413 883 0.310 0.035 3.21E-18
TwinsUK T C I 0.256 577 0.188 0.035 9.01E-08
combined T C - 0.346 4206 0.272 0.018 1.68E-51
validation T C G 0.352 2125 0.345 0.025 5.82E-42
rs2896526 11 LDHA/LDHC KORA S4 G A I 0.177 1785 0.265 0.033 3.99E-15
subregion LURIC G A I 0.181 961 0.271 0.079 6.58E-04
Sorbs G A I 0.163 883 0.226 0.048 3.00E-06
TwinsUK G A I 0.156 582 0.123 0.042 3.27E-03
combined G A - 0.172 4211 0.221 0.023 4.12E-22
validation G A G 0.187 2097 0.216 0.031 8.18E-12
rs12753193 1 1p31 (LEPR) KORA S4 A G I 0.613 1785 0.103 0.027 1.94E-04
region LURIC A G I 0.601 961 0.094 0.064 1.44E-01
Sorbs A G I 0.599 883 0.177 0.038 4.15E-06
TwinsUK A G G 0.628 583 0.133 0.033 5.86E-05
combined A G - 0.609 4212 0.125 0.018 1.22E-11
validation A G G 0.606 2127 0.085 0.025 8.60E-04
rs549485 11 11p14 (SERGEF) KORA S4 T C G 0.335 871 0.155 0.040 9.77E-05
males only region LURIC T C G 0.368 691 0.105 0.076 1.17E-01
Sorbs T C G 0.309 361 0.272 0.144 3.18E-05
combined T C - 0.342 1923 0.173 0.031 2.76E-08
vlidation* C G G 0.349 1049 0.091 0.035 8.50E-03
*In the validation analysis rs549485 was replaced by rs493767 (r
2=0.961, 3rd lowest p-value within this region in the gender stratified meta-analysis) for technical
reasons.
doi:10.1371/journal.pgen.1001213.t001
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to the restrictions in laboratory methods our analyses were
confined to the A-SAA isoforms and did not capture the
constitutively expressed C-SAA isoform which might also be of
interest, especially when analyzing baseline SAA levels. Secondly,
the number of studies with genome-wide data and measured A-
SAA levels was limited compared to other genome-wide
association studies. Nevertheless, the study had enough power to
detect two novel genetic susceptibility regions for A-SAA which
explain 19.76% of the total estimated heritability already.
Furthermore, results were consistent across all four studies and
within different genotyping platforms, the regions are biologically
highly plausible, and the results may contribute to future research
on the regulation of inflammatory response and its role in related
clinical entities.
Taken together, the present meta-analysis is the first whole
genome approach to identify genetic variants that are associated
with baseline A-SAA concentrations. Two novel genetic suscep-
tibility regions were identified to be associated with baseline A-
SAA concentrations. The findings demonstrate a major impact of
the 11p15.5-p13 gene region on the regulation of inflammation
and suggest a close interplay between leptin, A-SAA, and other
acute-phase proteins as well as a larger role of the LEPR gene locus
in inflammatory processes as it has been assumed in the past.
Materials and Methods
Participating studies
The present meta-analysis combined data from four genome-
wide scans: one survey of the Cooperative Health Research in the
Region of Augsburg (KORA S4), the Ludwigshafen Risk and
Cardiovascular Health study (LURIC), the UK Adult Twin
Register (TwinsUK) and a self-contained population from Eastern
Germany (Sorbs) (Text S1). Approval was obtained by each of the
local Ethic Committees for all studies and written informed
consent was given by all study participants. In total, the meta-
analysis included 4,212 individuals (1,928 males, 2,284 females) of
European ancestry with measured baseline A-SAA concentrations.
For validation analyses we used data of 2,136 participants of the
KORA S4 sample, which were not included in the meta-analysis
(Text S1). Sample sizes and characteristics of the study participants
of the four genome-wide scans and the validation sample are
displayed in Table S6.
Measurement of A-SAA concentrations
In all four studies, study participants were fasting and EDTA
plasma samples were analyzed by immunonephelometry on a
BNAII device from Siemens, Germany, and well-validated
automated microparticle capture enzyme immunoassays [10,41].
The inter-assay coefficients of variation were below 7% in all four
studies.
Genome-wide genotyping and imputation
For genotyping different platforms as the Affymetrix 500K
GeneChip array (Sorbs), Affymetrix 6.0 GeneChip array (KORA
S4, LURIC, Sorbs), Illumina HumanHap300 BeadChip (317K)
(TwinsUK) and Illumina Human 610K BeadChip (TwinsUK)
were used. Quality control before imputation was undertaken in
each study separately. Detailed information on genotyping and
imputation is reported in Table S7. Imputation based on the
HapMap Phase 2 CEU population was performed using IMPUTE
[42] in all studies. After imputation all genotype data had to meet
the following quality criteria: a minor allele frequency $0.01, a
call rate per SNP $0.9, and r
2.hat metrics $0.40 for imputed
SNPs. In total, 2,593,456 genotyped or imputed autosomal SNPs
were analyzed in the meta-analysis.
For validation and comparison of genotyping platforms, we
selected 27 of the most significantly associated SNPs. Genotyping
of these SNPs was performed with the MassARRAY system using
the iPLEX technology (Sequenom, San Diego, CA) in the KORA
S4 study. The allele-dependent primer extension products were
loaded onto one 384-element chip using a nanoliter pipetting
system (SpectroCHIP, Spectro-POINT Spotter; Sequenom), and
the samples were analyzed by matrix-assisted laser desorption-
ionization time-of-flight mass spectrometry (Bruker Daltonik,
Leipzig, Germany). The resulting mass spectra were analyzed
for peak identification via the SpectroTYPER RT 3.4 software
(Sequenom). To control for reproducibility, 9.8% of samples was
genotyped in duplicate with a discordance rate of less than 0.5%.
Genome-wide association analyses and meta-analysis
In each study, linear regression models for all available SNPs
have been calculated on ln-transformed A-SAA levels in mg/l.
The genetic effect has been assumed to be additive. Adjustment
has been made for age, gender, BMI, and study specific covariates,
i.e. the Friesinger Score in the LURIC population [43] and a
genotyping batch variable in the TwinsUK population. Addition-
ally, this analysis was undertaken stratified by gender. The
genome-wide scans were calculated with the analysis software
SNPTEST (http://www.stats.ox.ac.uk/,marchini/software/gwas/
snptest.html) (KORA S4, LURIC) QUICKTEST (http://toby.
freeshell.org/software/quicktest.shtml) (Sorbs) and Merlin (http://
www.sph.umich.edu/csg/abecasis/Merlin/) (TwinsUK).
The results of all four genome-wide scans were meta-analysed
using a fixed-effects model applying inverse variance weighting with
the METAL software (www.sph.umich.edu/csg/abecasis/metal).
Study specific results were corrected for population stratification
using the genomic control method. For the overall meta-analysis,
the inflation factor was 1.009. No further correction was applied.
P-values below the threshold of p=5610
28, which corresponds
to a Bonferroni correction for the estimated number of one million
tests for independent common variants in the human genome of
European individuals [44], were considered to be significant.
As a measure for between study heterogeneity I
2 was calculated
[45]. Deviations from Hardy-Weinberg-Equilibrium were tested
for all identified SNPs by means of the exact Hardy Weinberg test.
For the calculation of explained variances, we subtracted the
multiple R
2 value of the covariate model from those of the full
model including covariates and top hits of the loci in every single
study and assessed the weighted mean (KORA S4, LURIC, and
the Sorbs). We tested adjacent regions for independency by
analyzing the significance of their top SNPs in a joint model.
Accession numbers
The OMIM (http://www.ncbi.nlm.nih.gov/omim) accession
numbers for genes mentioned in this article are 104750 for SAA1,
Figure 2. Regional plots of the genetic susceptibility regions/subregions. The regional plots present gene regions and block structures of
the region at 11p15.5-p13 (A), the SAA1 subregion (B), the HPS5/GTF2H1 subregion (C), the LDHA/LDHC subregion (D), and the region at 1p31 (E) and
picture the probability values of the significantly associated SNPs, the colour representing the degree of correlation with the top hit of the respective
region/subregion.
doi:10.1371/journal.pgen.1001213.g002
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for LDHC, 601007 for LEPR, and 606051 for SERGEF.
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